Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | FF-21101(90Y) |
Synonyms | |
Therapy Description |
FF-21101(90Y) is an yttrium Y 90-labeled anti-human cadherin-3 (CDH3) antibody, which selectively delivers radiation to CDH3-positive cancer cells, potentially leading to tumor growth inhibition (PMID: 32816889). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FF-21101(90Y) | 90 Y-FF-21101|90Y-FF-21101 | FF-21101(90Y) is an yttrium Y 90-labeled anti-human cadherin-3 (CDH3) antibody, which selectively delivers radiation to CDH3-positive cancer cells, potentially leading to tumor growth inhibition (PMID: 32816889). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02454010 | Phase I | FF-21101(90Y) | A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer | Completed | USA | 0 |